PEDIATRICS Vol. 70 No. 5 November 1982, pp. 824-825
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bourgeois, B. F. D.
Right arrow Articles by Ferrendelli, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bourgeois, B. F. D.
Right arrow Articles by Ferrendelli, J. A.

Isoniazid and Other Drugs

Blaise F. D. Bourgeois MD1, W. Edwin Dodson MD1, and James A. Ferrendelli MD1

1 Division of Clinical Neuropharmacology, Division of Child Neurology, Department of Neurology and Neurosurgery, (Neurology), and Pharmacology, Edward Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St Louis, MO 63110

We read with interest the paper by Block on carbamazepine-isoniazid interaction.1 Although this report mentions that isoniazid has been previously shown to interfere with phenytoin metabolism,2 it fails to mention the interaction between isoniazid and primidone. Sutton and Kupferberg3 have described a patient in whom the addition of isoniazid prolonged the half-life of primidone (Mysoline) and decreased its biotransformation to phenobarbital and phenylethylmalonamide (PEMA). In 1964, Kato et a14 had already demonstrated the inhibitory effect of isoniazid on the metabolism of certain barbiturates in vitro.